OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
PETALUMA, Calif., Feb. 05, 2016 -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (tradable warrants OCLSW) today announced that Jim Schutz, chief executive officer, and Bob Miller, chief financial officer, will present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference to be held at the Convene Conference Center, 730 Third Avenue, New York City on Wednesday, February 10, 2016 at 9:30am ET. Management will also be meeting with investors throughout the day.
About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.
Media and Investor Contact: Oculus Innovative Sciences, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105 [email protected]
